U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Size, Share & Trends Analysis Report By End-use (Cardiac Arrest, Aortic Occlusion, Tactical Combat Casualty Care), And Segment Forecasts, 2025 - 2030

U.S. REBOA Market Size & Trends

The U.S. resuscitative endovascular balloon occlusion of the aorta market size was valued at USD 7.2 million in 2024 and is projected to grow at a CAGR of 23.6% from 2025 to 2030. Key players such as Prytime Medical and Emergency Scientific, LLC drive REBOA device innovation in the U.S. through strategic collaborations, mergers, and acquisitions. Products like the Landmark REBOA Catheter convenience kit enhance procedural efficiency, while recent FDA approvals boost market growth. These advancements improve accessibility and effectiveness, expanding the market presence of resuscitative endovascular balloon occlusion of the aorta (REBOA) devices.

The growing number of traumatic injuries from road accidents, falls, and violence is a key factor fueling the U.S. REBOA market. This surge in critical cases increases the demand for effective emergency interventions such as REBOA. As a result, advancements and adoption of these life-saving devices continue to expand. According to the U.S. Bureau of Labor Statistics (BLS), in 2022, there were 5,486 fatal work injuries in the United States, marking a 5.7% increase from 2021. Transportation incidents were the leading cause, accounting for 37.7% of these fatalities. In 2023, the number of fatal work injuries decreased by 3.7% to 5,283, with transportation incidents remaining the most frequent cause, comprising 36.8% of fatalities.

Advancements in medical technology have greatly improved the safety and effectiveness of REBOA procedures. Innovations such as enhanced balloon designs, advanced catheter systems, and improved imaging allow for more precise placement and monitoring. These improvements lead to better patient outcomes and increased adoption of REBOA in trauma care. For instance, in June 2024, Utah-based Emergency Scientific announced the first use of its Landmark REBOA catheter after receiving FDA 510(k) clearance. The device is designed for temporary occlusion of large vessels to control emergency hemorrhages. Its advanced design improves occlusion precision while reducing complications compared to traditional methods.

Increasing healthcare spending is fueling the expansion of the U.S. REBOA industry. Higher investments in advanced medical technologies and trauma care are boosting the adoption of REBOA devices. This growth supports better emergency interventions and improved patient outcomes. According to the Centers for Medicare & Medicaid Services, in 2023, healthcare spending in the U.S. reached USD 4.9 trillion, marking a 7.5% increase, up from 4.6% in 2022. Medicare and private health insurance spending grew faster than in 2022. In 2023, the health sector accounted for 17.6% of the economy, comparable to 17.4% in 2022, but this figure is lower than the shares recorded in 2020 and 2021 at the height of the COVID-19 pandemic.

Market Concentration & Characteristics

The industry growth stage is medium, with an accelerating pace. Advancements in medical technology are driving improvements in trauma care and bleeding control. Innovations such as new balloon designs, biocompatible materials, and integrated real-time monitoring systems are enhancing the effectiveness of procedures. For instance, in March 2023, Prytime Medical launched the PROMPT Observational Clinical Trial, the first prospective in-human study of Partial REBOA using its pREBOA-PRO catheter. Backed by a nearly USD 6 million grant from the U.S. Department of Defense, the study aims to evaluate the clinical effectiveness of Partial REBOA across multiple trauma centers in the U.S. and Canada.

The level of mergers and acquisitions in the U.S. REBOA industry is considered moderate. While there have not been many notable mergers and acquisitions among companies specializing in vascular devices and trauma care technologies, the market remains relatively niche compared to broader medical device sectors. Companies increasingly look to consolidate resources, enhance their technological capabilities, and expand their market reach through strategic acquisitions.

Regulatory frameworks, particularly FDA standards, play a crucial role in the U.S. REBOA market by ensuring device safety and effectiveness. Strict approval processes impact market entry and innovation in REBOA technology. For instance, in June 2021, Front Line Medical Technologies announced FDA clearance for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), the smallest 4 French REBOA device available. This compact, innovative device enables rapid deployment to manage severe bleeding in emergencies, helping to minimize procedure time and complications.

The U.S. REBOA industry is witnessing steady growth across different regions, fuelled by advancements in trauma care and rising awareness among healthcare professionals about its effectiveness in treating hemorrhagic shock.

End Use Insights

The aortic occlusion segment dominated the industry and accounted for a revenue share of 61.1% of the U.S. market revenue in 2024. The primary causes of aortic occlusion include large saddle emboli at the aortic bifurcation, in situ thrombosis in an atherosclerotic aorta, and the blockage of previously performed surgical reconstructions. According to the April 2022 report published by the Journal of the American College of Emergency Physicians Open, Acute Aortic Occlusion (AAO) is a rare condition, with an estimated incidence of 3.8 cases per 1 million person-years—mortality rates for AAO range from 17% to 52% in 2021.

The cardiac arrest segment is expected to grow at the fastest CAGR of 31.6% over the forecast period. The high incidence of out-of-hospital cardiac arrests resulting in fatalities highlights the need for effective emergency interventions such as REBOA. The American Heart Association's Heart and Stroke Statistics - 2022 highlighted that cardiac arrest remains a major public health concern. The report states that over 356,000 out-of-hospital cardiac arrests (OHCA) occur annually in the U.S., with nearly 90% resulting in fatalities.

Key U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Company Insights

Some of the key companies operating in the market include Prytime Medical Devices, Inc., Emergency Scientific, LLC, Qx Médical, and Front Line Medical Technologies.

• Prytime Medical Devices, Inc. specializes in advanced technologies for trauma care. Their flagship product, the ER-REBOA catheter, is designed for temporary occlusion of large vessels in patients with severe hemorrhage. The company focuses on improving patient outcomes in emergency medical situations through innovative, minimally invasive solutions.

• Emergency Scientific, LLC specializes in providing innovative emergency response and disaster management solutions. They focus on developing advanced technologies and systems to improve safety and efficiency in critical situations. Their services support first responders and emergency services in managing complex scenarios effectively.

Recent Developments

• In June 2024, Emergency Scientific, LLC successfully utilized its Landmark catheter for the first time in REBOA. This innovative device, which was granted FDA 510(k) clearance, is designed for temporary occlusion of large vessels to manage emergency hemorrhage control.

• In March 2023, the U.S. Department of Defense granted Prytime Medical, Inc. USD 6 million through the Medical Technology Enterprise Consortium (MTEC). This funding would support a study on the clinical benefits of Partial REBOA at eight trauma centers in the U.S. and Canada using the pREBOA-PRO catheter, the first specifically designed for Partial REBOA. 

U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Scope

U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. resuscitative endovascular balloon occlusion of the aorta market report based on end use:

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Aortic Occlusion

• Cardiac Arrest

• Tactical Combat Casualty Care